Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-833923 plus Dasatinib in CML
NCT01218477Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of BMS-833923 in chronic myeloid leukemia (CML), sponsored by Bristol Myers Squibb. Started Jan 2011; status: completed.
02
Drugs
BMS-833923
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01218477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01218477.